Romiplostim

In plain language

Romiplostim is a once-weekly injection for immune thrombocytopenia (ITP), a condition where the immune system destroys platelets and bruising and bleeding result. It is sold as Nplate.

It is a "peptibody," a hybrid molecule: a peptide that activates the receptor for thrombopoietin (the hormone that tells bone marrow to make platelets) welded to part of an antibody so it lasts a week. It was discovered by screening billions of random peptide fragments for ones that touch the right receptor.

For students

Romiplostim is a peptibody (about 59 kDa) consisting of two disulfide-linked peptides containing the active sequence, each fused to an IgG1 Fc domain, extending half-life to about 120-160 hours. The peptide motif was identified by phage display against the thrombopoietin receptor (c-Mpl) and shares no sequence homology with thrombopoietin itself, activating the receptor as a functional mimetic rather than a structural one.

Two randomized placebo-controlled trials (n=63 splenectomized and n=62 non-splenectomized chronic ITP patients) showed durable platelet response in the majority of romiplostim patients versus none or few on placebo; extension studies showed response maintenance for years. Safety monitoring includes reticulin bone marrow changes and thrombocytosis, with dose titration to a target platelet count of 50-250 x 10^9/L. It is also approved for ITP in children and for use in chronic hepatitis C thrombocytopenia scenarios in some regions.

For researchers and instructors

Biochemistry. The phage-display discovery route and the Fc-fusion half-life extension are two transferable engineering lessons in one molecule; the peptide does not compete with thrombopoietin, so combined dosing is not additive at the receptor level.

Pharmacology. Weekly subcutaneous dosing starting at 1 mcg/kg titrated by platelet response; abrupt discontinuation can rebound thrombocytopenia; reticulin surveillance is recommended for long-term use.

Human evidence. Two pivotal randomized trials (placebo-controlled, response rates 38-88% depending on stratum versus 0-14% placebo) plus long-term extension cohorts of over 1,000 patient-years.

Teaching point. The archetypal peptibody: teaches both phage display as a discovery platform and Fc fusion as a half-life platform in a single approved drug.